Prognostic implications of ERLncRNAs in ccRCC: a novel risk score model and its association with tumor mutation burden and immune microenvironment

Abstract Introduction/background The specific role of efferocytosis-related long noncoding RNAs (ERLncRNAs) in Clear Cell Renal Cell Carcinoma (ccRCC) has not been thoroughly examined. This study aims to identify and validate a signature of ERLncRNAs for prognostic prediction and characterization of...

Full description

Saved in:
Bibliographic Details
Main Authors: Kunlun Feng, Jingxiang Li, Jianye Li, Zhichao Li, Yahui Li
Format: Article
Language:English
Published: Springer 2025-02-01
Series:Discover Oncology
Subjects:
Online Access:https://doi.org/10.1007/s12672-025-01870-3
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849724150014279680
author Kunlun Feng
Jingxiang Li
Jianye Li
Zhichao Li
Yahui Li
author_facet Kunlun Feng
Jingxiang Li
Jianye Li
Zhichao Li
Yahui Li
author_sort Kunlun Feng
collection DOAJ
description Abstract Introduction/background The specific role of efferocytosis-related long noncoding RNAs (ERLncRNAs) in Clear Cell Renal Cell Carcinoma (ccRCC) has not been thoroughly examined. This study aims to identify and validate a signature of ERLncRNAs for prognostic prediction and characterization of the immune landscape in individuals with ccRCC. Materials and methods Analysis of ccRCC samples was conducted by utilizing clinical and RNA sequencing information obtained from The Cancer Genome Atlas (TCGA). Pearson correlation analysis was utilized to identify lncRNAs associated with efferocytosis, which was then used to create a new prognostic model through univariate Cox regression, Least Absolute Shrinkage and Selection Operator (LASSO) regression, and stepwise multivariate Cox analysis. In order to investigate the biological significance, we performed a functional enrichment analysis to assess how well the model predicts outcomes. Differences in the immune landscape were observed through a comparison of immune cell infiltration, tumor mutational burden (TMB), and tumor microenvironment (TME) characteristics. Following this, drug sensitivity analysis was conducted. Results This led to the identification of a unique signature consisting of seven ERLncRNAs (LINC01615, RUNX3-AS1, FOXD2-AS1, AC002070.1, LINC02747, LINC00944, and AC092296.1). Model performance was measured by Kaplan–Meier curves and receiver operating characteristic (ROC) curves. The nomogram and C-index provided additional validation of the strong correlation between the risk signature and clinical decision-making. Conclusion On the whole, our innovative signature exhibits potential for prognostic prediction and assessment of immunotherapeutic response in patients with ccRCC.
format Article
id doaj-art-3a4c02cdfcd249419affdebfa5a62350
institution DOAJ
issn 2730-6011
language English
publishDate 2025-02-01
publisher Springer
record_format Article
series Discover Oncology
spelling doaj-art-3a4c02cdfcd249419affdebfa5a623502025-08-20T03:10:50ZengSpringerDiscover Oncology2730-60112025-02-0116112410.1007/s12672-025-01870-3Prognostic implications of ERLncRNAs in ccRCC: a novel risk score model and its association with tumor mutation burden and immune microenvironmentKunlun Feng0Jingxiang Li1Jianye Li2Zhichao Li3Yahui Li4Shandong University of Traditional Chinese MedicineThe Second Affiliated Hospital of Shandong University of Traditional Chinese MedicineThe Second Affiliated Hospital of Shandong University of Traditional Chinese MedicineThe Second Affiliated Hospital of Shandong University of Traditional Chinese MedicineThe Second Affiliated Hospital of Shandong University of Traditional Chinese MedicineAbstract Introduction/background The specific role of efferocytosis-related long noncoding RNAs (ERLncRNAs) in Clear Cell Renal Cell Carcinoma (ccRCC) has not been thoroughly examined. This study aims to identify and validate a signature of ERLncRNAs for prognostic prediction and characterization of the immune landscape in individuals with ccRCC. Materials and methods Analysis of ccRCC samples was conducted by utilizing clinical and RNA sequencing information obtained from The Cancer Genome Atlas (TCGA). Pearson correlation analysis was utilized to identify lncRNAs associated with efferocytosis, which was then used to create a new prognostic model through univariate Cox regression, Least Absolute Shrinkage and Selection Operator (LASSO) regression, and stepwise multivariate Cox analysis. In order to investigate the biological significance, we performed a functional enrichment analysis to assess how well the model predicts outcomes. Differences in the immune landscape were observed through a comparison of immune cell infiltration, tumor mutational burden (TMB), and tumor microenvironment (TME) characteristics. Following this, drug sensitivity analysis was conducted. Results This led to the identification of a unique signature consisting of seven ERLncRNAs (LINC01615, RUNX3-AS1, FOXD2-AS1, AC002070.1, LINC02747, LINC00944, and AC092296.1). Model performance was measured by Kaplan–Meier curves and receiver operating characteristic (ROC) curves. The nomogram and C-index provided additional validation of the strong correlation between the risk signature and clinical decision-making. Conclusion On the whole, our innovative signature exhibits potential for prognostic prediction and assessment of immunotherapeutic response in patients with ccRCC.https://doi.org/10.1007/s12672-025-01870-3EfferocytosisccRCCLncRNAPrognosticImmunityTumor mutation burden
spellingShingle Kunlun Feng
Jingxiang Li
Jianye Li
Zhichao Li
Yahui Li
Prognostic implications of ERLncRNAs in ccRCC: a novel risk score model and its association with tumor mutation burden and immune microenvironment
Discover Oncology
Efferocytosis
ccRCC
LncRNA
Prognostic
Immunity
Tumor mutation burden
title Prognostic implications of ERLncRNAs in ccRCC: a novel risk score model and its association with tumor mutation burden and immune microenvironment
title_full Prognostic implications of ERLncRNAs in ccRCC: a novel risk score model and its association with tumor mutation burden and immune microenvironment
title_fullStr Prognostic implications of ERLncRNAs in ccRCC: a novel risk score model and its association with tumor mutation burden and immune microenvironment
title_full_unstemmed Prognostic implications of ERLncRNAs in ccRCC: a novel risk score model and its association with tumor mutation burden and immune microenvironment
title_short Prognostic implications of ERLncRNAs in ccRCC: a novel risk score model and its association with tumor mutation burden and immune microenvironment
title_sort prognostic implications of erlncrnas in ccrcc a novel risk score model and its association with tumor mutation burden and immune microenvironment
topic Efferocytosis
ccRCC
LncRNA
Prognostic
Immunity
Tumor mutation burden
url https://doi.org/10.1007/s12672-025-01870-3
work_keys_str_mv AT kunlunfeng prognosticimplicationsoferlncrnasinccrccanovelriskscoremodelanditsassociationwithtumormutationburdenandimmunemicroenvironment
AT jingxiangli prognosticimplicationsoferlncrnasinccrccanovelriskscoremodelanditsassociationwithtumormutationburdenandimmunemicroenvironment
AT jianyeli prognosticimplicationsoferlncrnasinccrccanovelriskscoremodelanditsassociationwithtumormutationburdenandimmunemicroenvironment
AT zhichaoli prognosticimplicationsoferlncrnasinccrccanovelriskscoremodelanditsassociationwithtumormutationburdenandimmunemicroenvironment
AT yahuili prognosticimplicationsoferlncrnasinccrccanovelriskscoremodelanditsassociationwithtumormutationburdenandimmunemicroenvironment